Bio-Techne Shareholders Clear Path for Merck KGaA Acquisition

Bio-Techne's shareholders have approved its acquisition by Merck KGaA. The deal was met with regulatory scrutiny, but ultimately cleared after a thorough review process. This marks a significant milestone in the biotech industry.

The acquisition is expected to bring together two leading companies in the field of life sciences research and development. Bio-Techne's shareholders have given their approval for the merger, which will see Merck KGaA take control of the company.